Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-06-18

Breaking Tolerance - Combination of Virotherapy and Immunotherapy for Cancer Treatment

Objective

The aim of this project is to enhance the efficacy of a tumour killing virus and break tolerance within the tumour to induce an immune response against the primary tumour and metastatic deposits. The proposed strategy requires three steps. First, the tumour immunological microenvironment needs to be reset as tumours utilize a variety of mechanisms to escape host immune system. Here, we propose to use the chemotherapeutic agent cyclophosphamide to temporally deplete suppressor T cells and recruit new dentritic cell progenitors. Second, to kill cancer cells, we propose to systemically deliver the potent tumour-killing (oncolytic) adenovirus ICOVIR15, which replicates selectively in cancer cells with pRB pathway mutations. In order to favour anti-tumour immunity, the ICOVIR15 will be genetically engineered to express cytokines that have been shown to be useful to stimulate anti-tumour responses such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon-gamma (IFN-g). Moreover, IFN-g has also been shown to kill tumour-associated vasculature. The host group has been awarded with three “non-commercial” clinical research grants from the “Fondo de Investigaciones Sanitarias” of the Ministry of Innovation and Science of Spain to test ICOVIR5 in clinical trials. ICOVIR5 is being produced under Good Manufacturing Practices. If the novel GM-CSF or IFNg armed viruses show promising results at preclinical level, the host group will apply for other non-commercial research grants to test it in clinical trials. This project is also aimed at further developing the skills of the applicant in genetic engineering, virotherapy, immunology and working in different tumour models. The applicant would move from the UK to Spain. The applicant hopes to establish herself as an expert in the multidisciplinary areas of cancer gene therapy such as immunotherapy, angiotherapy and virotherapy.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP7-PEOPLE-2009-IEF
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

MC-IEF - Intra-European Fellowships (IEF)

Coordinator

FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE
EU contribution
€ 153 917,00
Address
AVENIDA GRAN VIA HOSPITALET 199-203
08908 L'Hospitalet De Llobregat
Spain

See on map

Region
Este Cataluña Barcelona
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data
My booklet 0 0